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EORTC Oncology Research Conference Annual Meeting Treatment Emergent Adverse Events (TEAE) > 10% and Clinically Significant Events
(n = number of subjects experiencing an event)
Results
ME-344, a Novel Mitochondrial Oxygenase Inhibitor: Results From a First-In-Human Phase I Study
• The ME-344 Maximum Tolerated Dose and the Recommended Phase 2 Dose was established at 10 mg/kg IV weekly • The primary DLT was peripheral neuropathy consistent with the proposed mechanism of action • At doses <10 mg/kg ME-344 was generally well tolerated for extended durations • Pharmacokinetics suggest a linear relationship between dose, C max and AUC with T 1/2 of approximately 6 hours • Evidence of clinical activity was demonstrated:
• 1 subject with confirmed PR (61+ weeks)
• 4 subjects with prolonged SD (34 -49+ weeks)
• Defined as at least twice the duration of their immediately prior therapy • 4 subjects remain on study drug with a range of 34 -61 weeks • Further clinical development of ME-344 is warranted
• A 3+3 dose escalation design was utilized • 5 dose cohorts were planned: 1.25, 2.5, 5, 10, and 20mg/kg
• An intermediate 15 mg/kg dose level was explored • ME-344, formulated in 30% Captisol®, was administered IV over 30 minutes, weekly times 3, followed by a 1 week break (28 day cycle), and then continuous weekly dosing until progressive disease (PD) or unacceptable toxicity • Standard eligibility criteria were utilized including age > 18 years, the diagnosis of a solid tumor with no standard treatment options, ECOG PS < 2, adequate organ function, and a normal QTc interval • Dense PK sampling was performed at 0, 5, 10, 20, 30 60, 90, 120, 180, 240, 300, 360 minutes and 24 hours post-infusion day 1 and 15 of the first treatment cycle • A Dose Limiting Toxicity (DLT) was defined as a NCI CTCAE v4.0 > grade 3 occurring after the first 28 Days and judged by the investigator as possibly, probably or definitely related to study drug • Tumor assessments were required at least every 12 weeks and scored according to RECIST v1.1.
• Between May 17, 2012 and March 18, 2013, 30 subjects were enrolled • The data cut-off is October 15, 2013
Pharmacokinetic Results
Scan code for more information Figure 1 • In preclinical studies, ME-344 displayed a high degree of efficacy against a broad range of cell lines from various tissues
• ME-344 is a second generation isoflavone-derived compound • ME-344 is derived from the demethylated metabolite of NV-128, the first generation molecule in this class • ME-344 causes caspase-independent cell death in multiple human tumor cell lines including CD44+/MyD88+ ovarian cancer stem cells by interfering with mitochondrial energy generation • Treatment with ME-344 results in decreased mitochondrial ATP production and increased reactive oxygen species, with subsequent disruption of tumor cell mitochondrial integrity • Decreased ATP leads to formation of autophagic vacoules via activation of AMP kinase and mTOR1 and mTOR-2-dependent signaling pathways [see 
